New midday Pick- PETX short

Petx just had a prelim study come out that showed promising results for dog for arthritis. The drug hasnt gone through any FDA channels as of yet and still has to undergo the certification process. They dont expect the drug to hit the market until 2016, which translated means no money until 2016 and thats if the FDA tests it and clears it. The options spread on this stock suck, so we are just going to go right ahead and short this one.

Aratana Therapeutics, Inc. (PETX)

 -NasdaqGM  Watchlist

15.48  2.41(18.44%) 12:59PM EST - Nasdaq Real Time Price

Add to Portfolio

Prev Close:	13.07
Open:	15.77
Bid:	15.41 x 100
Ask:	15.48 x 400
1y Target Est:	25.25
Beta:	5.808
Earnings Date:	Mar 11 - Mar 16 (Est.)

Thats all for today, look for another update this evening.

Stay Frosty,
Mark